ATF6 and neoplasm: Aberrant activation of the UPR sensors (IRE1α-XBP1, PERK-ATF4, ATF6) and their downstream signaling pathways have emerged as critical regulators of tumor angiogenesis, metastasis, and response to chemotherapy, targeted therapy, and immunotherapy.